+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Pancreatic Cancer

  • ID: 4775094
  • Report
  • February 2021
  • Region: Global
  • 60 pages
  • Datamonitor Healthcare

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Eli Lilly
  • Five Prime Therapeutics
  • Pfizer
  • Roche
This Market Spotlight report covers the Pancreatic Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2019, there were 462,100 incident cases of pancreatic cancer worldwide, and expects that number to increase to 486,300 incident cases by 2028.

The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, poly ADP-ribose polymerase, dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor. These drugs are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.

The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II. Therapies in development for pancreatic cancer focus on a wide variety of targets. The majority of pipeline drugs for pancreatic cancer are administered via the oral or intravenous routes.

High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase II/III, Phase II, and Phase III trial results, and an expected patent expiration.

The overall likelihood of approval of a Phase I pancreatic cancer asset is 2%, and the average probability a drug advances from Phase III is 13.8%. Drugs, on average, take 10.7 years from Phase I to approval, compared to 9.5 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for pancreatic cancer have been in the early and mid-phases of development, with 93% of trials in Phase I-II, and only 7% in Phase III-IV.

The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the pancreatic cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 103 trials.

Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for pancreatic cancer, followed by Roche
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Eli Lilly
  • Five Prime Therapeutics
  • Pfizer
  • Roche
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
  • Subtypes
TREATMENT
  • Surgery
  • Ablation or embolization
  • Radiation therapy
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
  • Drugs used specifically for the treatment of PNETs
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • Motixafortide for Pancreatic Cancer (January 24, 2020)
  • Lynparza for Pancreatic Cancer (December 17, 2019)
  • Pegilodecakin for Pancreatic Cancer (October 16, 2019)
  • Acelarin for Pancreatic Cancer (August 20, 2019)
  • Mavorixafor for Pancreatic Cancer (July 17, 2019)
  • Napabucasin for Pancreatic Cancer (July 1, 2019)
  • Abraxane for Pancreatic Cancer (June 2, 2019)
  • Lynparza for Pancreatic Cancer (June 2, 2019)
  • NanoKnife System for Pancreatic Cancer (May 13, 2019)
  • MVT-5873 for Pancreatic Cancer (May 8, 2019)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • Lynparza Gets US OK For Pancreatic Cancer
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • Cytocom Goes Public Via Merger With Cleveland BioLabs
  • Exact Goes All-In On Multi-Cancer Screening With $2.15Bn For Thrive; $410M For Base Genomics
  • TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens
  • Processa Licenses IP For Next-Generation Irinotecan From Aposense
  • Bristol Myers Squibb declines to exercise Agios Pharmaceuticals opt-in right for AG-270
  • DeMelle Licenses Pancreatic Cancer Candidate From Moffit
  • Taiho Acquires Asian Rights To Arcus IO Candidate
  • Tyme, Eagle Collaborate On Development Of Pancreatic Cancer Drug
  • Astellas Taps Pandion In Pancreas Immunomodulator Deal
REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
BIBLIOGRAPHY
  • Prescription information
APPENDIX

LIST OF FIGURES
Figure 1: Trends in incident cases of pancreatic cancer, 2019–28
Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
Figure 3: Pipeline drugs for pancreatic cancer, by company
Figure 4: Pipeline drugs for pancreatic cancer, by drug type
Figure 5: Pipeline drugs for pancreatic cancer, by classification
Figure 6: Motixafortide for Pancreatic Cancer (January 24, 2020): Phase Ib/II - w/Atezolizumab
Figure 7: Pegilodecakin for Pancreatic Cancer (October 16, 2019): Phase III - SEQUOIA (w/FOLFOX)
Figure 8: Lynparza for Pancreatic Cancer (June 2, 2019): Phase III - POLO
Figure 9: Key upcoming events in pancreatic cancer
Figure 10: Probability of success in the pancreatic cancer pipeline
Figure 11: Clinical trials in pancreatic cancer
Figure 12: Top 10 drugs for clinical trials in pancreatic cancer
Figure 13: Top 10 companies for clinical trials in pancreatic cancer
Figure 14: Trial locations in pancreatic cancer
Figure 15: Pancreatic cancer trials status
Figure 16: Pancreatic cancer trials sponsors, by phase

LIST OF TABLES
Table 1: Incident cases of pancreatic cancer, 2019–28
Table 2: Marketed drugs for pancreatic cancer
Table 3: Pipeline drugs for pancreatic cancer in the US
Table 4: Motixafortide for Pancreatic Cancer (January 24, 2020)
Table 5: Lynparza for Pancreatic Cancer (December 17, 2019)
Table 6: Pegilodecakin for Pancreatic Cancer (October 16, 2019)
Table 7: Acelarin for Pancreatic Cancer (August 20, 2019)
Table 8: Mavorixafor for Pancreatic Cancer (July 17, 2019)
Table 9: Napabucasin for Pancreatic Cancer (July 1, 2019)
Table 10: Abraxane for Pancreatic Cancer (June 2, 2019)
Table 11: Lynparza for Pancreatic Cancer (June 2, 2019)
Table 12: NanoKnife System for Pancreatic Cancer (May 13, 2019)
Table 13: MVT-5873 for Pancreatic Cancer (May 8, 2019)
Table 14: Historical global sales, by drug ($m), 2015–19
Table 15: Forecasted global sales, by drug ($m), 2020–24
Note: Product cover images may vary from those shown
  • Bristol-Myers Squibb
  • Eli Lilly
  • Five Prime Therapeutics
  • Pfizer
  • Roche
Note: Product cover images may vary from those shown
Adroll
adroll